Brenig Therapeutics
Biotechnology Research • 
United States • 1-10 Employees
Company overview
| Headquarters | United States |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Drug Development, Parkinson'S Disease, Neurodegenerative Disorders, Disease-Modifying Therapies, Small-Molecule Therapies |
| Employees | 1-10 |
| Socials |
Key Contact at Brenig Therapeutics
David L. Lucchino
Chief Executive Officer
Brenig Therapeutics Email Formats
Brenig Therapeutics uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@brenigther.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@brenigther.com | 66.7% |
{first initial}{last name} | jdoe@brenigther.com | 33.3% |
About Brenig Therapeutics
Brenig Therapeutics was co-founded in 2021 by OrbiMed, Torrey Pines, and BGV to design and develop breakthrough medicines for neurodegenerative disorders. Brenig’s mission is to build a robust portfolio of first- and best-in-class therapies targeting a broad spectrum of neurodegenerative diseases, starting with Parkinson’s disease. Our lead program is a potential best in class LRRK2 inhibitor developed using advanced AI-driven drug discovery models. This pioneering approach enabled the creation of a highly selective, brain-penetrant molecule that has rapidly progressed from discovery into clinical development.
Brenig Therapeutics revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | $65,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Brenig Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Belgium
Spain
Australia
United Kingdom
Frequently asked questions
4.8
40,000 users
